Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
RENOVA, Apr-Dec (Cumulative 3Q) Net Income Turns to Loss, Oct-Dec Net Income Turns to Loss
9519 RENOVA,Inc. 【IFRS】
Earnings ReportRENOVA,Inc. <9519> [TSE Prime] announced its financial results (based on IFRS) after the market closed on February 7th (15:30). The consolidated net income/loss for the cumulative third quarter of the fiscal year ending March 2025 (April to December) turned into a loss of 0.91 billion yen (compared to a profit of 5.98 billion yen in the same period last year).
Based on the cumulative third-quarter performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated net income for the January to March period (4Q) is expected to surge 2.4 times that of the same period last year, reaching 6.81 billion yen.
In the most recent three-month period, from October to December (3Q), the consolidated net income/loss turned to a loss of 0.78 billion yen (compared to a profit of 3.16 billion yen in the same period last year). However, the operating profit margin improved from 1.3% in the same period last year to 2.5%.
Kabutan News
Actual Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Progress Rate vs. First Half | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Apr - Dec, 2022 | 24,801 | 8,327 | 6,720 | 4,294 | 54.7 | 139.2 | Feb 9, 2023 | IFRS |
Apr - Dec, 2023 | 29,827 | 6,375 | 8,925 | 5,984 | 75.9 | 75.2 | Feb 7, 2024 | IFRS |
Apr - Dec, 2024 | 48,631 | 2,529 | -64 | -912 | -10.1 | ー | Feb 7, 2025 | IFRS |
YoY | +63.0% | -60.3% | - | - | - |
Current Period Guidance
Second Half Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Oct - Mar, 2023 | 26,197 | -1,216 | 6,518 | 6,039 | 76.6 | 0 | May 8, 2024 | IFRS |
Oct - Mar, 2024 Guidance | 38,111 | -1,152 | ー | 6,028 | 66.7 | 0 | Nov 7, 2024 | IFRS |
YoY | +45.5% | +5.3% | - | -0.2% | -13.0% |
Current Period Guidance
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Mar, 2023 | 33,581 | 8,870 | 4,829 | 2,678 | 34.1 | 0 | May 9, 2023 | IFRS |
Mar, 2024 | 44,748 | 5,017 | 11,864 | 8,857 | 112.3 | 0 | May 8, 2024 | IFRS |
Mar, 2025 Guidance | 71,800 | 1,000 | ー | 5,900 | 65.2 | 0 | May 8, 2024 | IFRS |
YoY | +60.5% | -80.1% | - | -33.4% | -41.9% |
Quarterly Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Oct - Dec, 2023 | 11,276 | 142 | 3,579 | 3,166 | 40.2 | 1.3 | Feb 7, 2024 | IFRS |
Jan - Mar, 2024 | 14,921 | -1,358 | 2,939 | 2,873 | 36.4 | -9.1 | May 8, 2024 | IFRS |
Apr - Jun, 2024 | 15,157 | 571 | 200 | 331 | 3.7 | 3.8 | Aug 8, 2024 | IFRS |
Jul - Sep, 2024 | 18,532 | 1,581 | 71 | -459 | -5.1 | 8.5 | Nov 7, 2024 | IFRS |
Oct - Dec, 2024 | 14,942 | 377 | -335 | -784 | -8.7 | 2.5 | Feb 7, 2025 | IFRS |
YoY | +32.5% | +165.5% | - | - | - |
Related Articles
NAKAMURA CHOUKOU, Apr-Dec (Cumulative 3Q) Operating Profit Turns to Profit, Oct-Dec Operating Profit Turns to Profit
Anicom Holdings, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 16%
TENMA, Apr-Dec (Cumulative 3Q) Ordinary Profit Decreases by 33%, Oct-Dec Ordinary Profit Decreases by 28%
SUMCO, 48% Decrease in Ordinary Profit for the Last Fiscal Year, Current period performance is undisclosed.
PORTERS, 10% Decrease in Ordinary Profit for The Current Fiscal Year
TS TECH, Apr-Dec (Cumulative 3Q) Net Income Decreases by 13%, Oct-Dec Net Income Decreases by 44%
Nissan Chemical, The Current Fiscal Year Ordinary Profit Revised Upward by 5%, Highest in Two Terms
Procrea Holdings, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 96%, Exceeds Full-Year Plan
TORII PHARMA, 35% Decrease in Ordinary Profit for The Current Fiscal Year
KAPPA CREATE, Apr-Dec (Cumulative 3Q) Ordinary Profit Decreases by 22%, Oct-Dec Ordinary Profit Decreases by 6%